UNSPSC 51162005: Aminophylline/ephedrine/guaifenesin/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162005 Aminophylline/ephedrine/guaifenesin/phenobarbital is a Commodity code that nominally covers a specific respiratory and stimulant pharmaceutical combination, but recent state and local procurement activity under this code shows significant mismatch with the abstract name. State and local buyers are actually procuring a much broader range of pharmaceutical products and pharmacy services — including naloxone and drug deactivation systems for public health response, comprehensive on-site pharmacy services for employee health plans, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals distributed through cooperative purchasing agreements. The issuing bodies span county health departments, county government employee health plans, state health agencies, and multi-state cooperative purchasing alliances. The scope reflects a shift toward integrated pharmacy-benefit management and opioid-response initiatives rather than procurement of the specific respiratory combination the code nominally describes.

Recent activity appears across Florida, Georgia, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health delivery. Hall County, Georgia issued RFQ/P #47-010 (due June 4, 2026) to contract a single vendor for on-site pharmacy services covering approximately 3,005 eligible employees and retirees under the county's group health insurance plans, with an 80/20 evaluation weighting 800 points on technical qualifications and 200 on cost. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with pricing weighted at 75 percent of the evaluation score and contracts effective July 1, 2026. The code shows low relevance to its nominal pharmaceutical combination and substantial recent activity in pharmacy services and generic drug procurement through both direct procurement and cooperative purchasing vehicles.